Literature DB >> 17051488

An outbreak of botulism in Thailand: clinical manifestations and management of severe respiratory failure.

Subsai Kongsaengdao1, Kanoksri Samintarapanya, Siwarit Rusmeechan, Adisorn Wongsa, Chaicharn Pothirat, Chairat Permpikul, Sunsanee Pongpakdee, Wilai Puavilai, Piraj Kateruttanakul, Uthai Phengtham, Kanlaya Panjapornpon, Jirayut Janma, Kunchit Piyavechviratana, Pasiri Sithinamsuwan, Athavudh Deesomchok, Surat Tongyoo, Warakarn Vilaichone, Kanokwan Boonyapisit, Saengduan Mayotarn, Benjamas Piya-Isragul, Aran Rattanaphon, Poj Intalapaporn, Petcharat Dusitanond, Piyathida Harnsomburana, Worapojn Laowittawas, Parnsiri Chairangsaris, Jithanorm Suwantamee, Wanna Wongmek, Ranistha Ratanarat, Akekarinth Poompichate, Hathai Panyadilok, Niwatchai Sutcharitchan, Apinya Chuesuwan, Petchdee Oranrigsupau, Chumpita Sutthapas, Surat Tanprawate, Jakapong Lorsuwansiri, Naritchaya Phattana.   

Abstract

BACKGROUND: Northern Thailand's biggest botulism outbreak to date occurred on 14 March 2006 and affected 209 people. Of these, 42 developed respiratory failure, and 25 of those who developed respiratory failure were referred to 9 high facility hospitals for treatment of severe respiratory failure and autonomic nervous system involvement. Among these patients, we aimed to assess the relationship between the rate of ventilator dependence and the occurrence of treatment by day 4 versus day 6 after exposure to bamboo shoots (the source of the botulism outbreak), as well as the relationship between ventilator dependence and negative inspiratory pressure.
METHODS: We reviewed the circumstances and timing of symptoms following exposure. Mobile teams treated patients with botulinum antitoxin on day 4 or day 6 after exposure in Nan Hospital (Nan, Thailand). Eighteen patients (in 7 high facility hospitals) with severe respiratory failure received a low- and high-rate repetitive nerve stimulation test, and negative inspiratory pressure was measured.
RESULTS: Within 1-65 h after exposure, 18 of the patients with severe respiratory failure had become ill. The typical clinical sequence was abdominal pain, nausea and/or vomiting, diarrhea, dysphagia and/or dysarthria, ptosis, diplopia, generalized weakness, urinary retention, and respiratory failure. Most patients exhibited fluctuating pulse and blood pressure. Repetitive nerve stimulation test showed no response in the most severe stage. In the moderately severe stage, there was a low-amplitude compound muscle action potential with a low-rate incremented/high-rate decremented response. In the early recovery phase, there was a low-amplitude compound muscle action potential with low- and high-rate incremented response. In the ventilator-weaning stage, there was a normal-amplitude compound muscle action potential. Negative inspiratory pressure variation among 14 patients undergoing weaning from mechanical ventilation was observed. Kaplan-Meier survival analysis identified a shorter period of ventilator dependency among patients receiving botulinum antitoxin on day 4 (P=.02).
CONCLUSIONS: Patients receiving botulinum antitoxin on day 4 had decreased ventilator dependency. In addition, for patients with foodborne botulism, an effective referral system and team of specialists are needed.

Entities:  

Mesh:

Year:  2006        PMID: 17051488     DOI: 10.1086/508176

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  23 in total

1.  Clinically and electrophysiologically diagnosed botulinum intoxication.

Authors:  Dilcan Kotan; Recep Aygul; Mustafa Ceylan; Yalcin Yilikoglu
Journal:  BMJ Case Rep       Date:  2013-01-03

2.  Safety and Improved Clinical Outcomes in Patients Treated With New Equine-Derived Heptavalent Botulinum Antitoxin.

Authors:  Patricia A Yu; Neal H Lin; Barbara E Mahon; Jeremy Sobel; Yon Yu; Rajal K Mody; Weidong Gu; Jennifer Clements; Hye-Joo Kim; Agam K Rao
Journal:  Clin Infect Dis       Date:  2017-12-27       Impact factor: 9.079

3.  Efficacy of Antitoxin Therapy in Treating Patients With Foodborne Botulism: A Systematic Review and Meta-analysis of Cases, 1923-2016.

Authors:  John C O'Horo; Eugene P Harper; Abdelghani El Rafei; Rashid Ali; Daniel C DeSimone; Amra Sakusic; Omar M Abu Saleh; Jasmine R Marcelin; Eugene M Tan; Agam K Rao; Jeremy Sobel; Pritish K Tosh
Journal:  Clin Infect Dis       Date:  2017-12-27       Impact factor: 9.079

4.  A Novel Rabbit Spirometry Model of Type E Botulism and Its Use for the Evaluation of Postsymptom Antitoxin Efficacy.

Authors:  Eran Diamant; Avi Pass; Osnat Rosen; Alon Ben David; Amram Torgeman; Ada Barnea; Arnon Tal; Amir Rosner; Ran Zichel
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

5.  Enhancing the Pharmacokinetic Properties of Botulinum Neurotoxin Serotype A Protease Inhibitors Through Rational Design.

Authors:  Petr Capek; Yan Zhang; Deborah J Barlow; Karen L Houseknecht; Garry R Smith; Tobin J Dickerson
Journal:  ACS Chem Neurosci       Date:  2011-06-15       Impact factor: 4.418

6.  Clinical Guidelines for Diagnosis and Treatment of Botulism, 2021.

Authors:  Agam K Rao; Jeremy Sobel; Kevin Chatham-Stephens; Carolina Luquez
Journal:  MMWR Recomm Rep       Date:  2021-05-07

7.  Evaluation of adamantane hydroxamates as botulinum neurotoxin inhibitors: synthesis, crystallography, modeling, kinetic and cellular based studies.

Authors:  Peter Šilhár; Nicholas R Silvaggi; Sabine Pellett; Kateřina Čapková; Eric A Johnson; Karen N Allen; Kim D Janda
Journal:  Bioorg Med Chem       Date:  2012-12-20       Impact factor: 3.641

8.  Onset dynamics of type A botulinum neurotoxin-induced paralysis.

Authors:  Frank J Lebeda; Michael Adler; Keith Erickson; Yaroslav Chushak
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-06-13       Impact factor: 2.745

9.  Identification and biochemical characterization of small-molecule inhibitors of Clostridium botulinum neurotoxin serotype A.

Authors:  Virginia Roxas-Duncan; Istvan Enyedy; Vicki A Montgomery; Vanessa S Eccard; Marco A Carrington; Huiguo Lai; Nizamettin Gul; David C H Yang; Leonard A Smith
Journal:  Antimicrob Agents Chemother       Date:  2009-06-15       Impact factor: 5.191

10.  A Novel Running Wheel Mouse Model for Botulism and Its Use for the Evaluation of Postsymptom Antitoxin Efficacy.

Authors:  Arieh Schwartz; Alon Ben David; Mordechai Hotoveli; Eyal Dor; Eran Diamant; Arik Vivyorka; Osnat Rosen; Amram Torgeman; Ran Zichel
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.